Company intelligence / Profile preview

ORCA Therapeutics

Amsterdam, North Holland, Netherlandsorca-therapeutics.nl ↗

Ownership: Private
Development stage: Phase 1

Overview

ORCA Therapeutics is developing novel immunotherapies using engineered oncolytic viruses. Their lead candidate, ORCA‑010, targets prostate cancer and is approaching clinical testing. The company’s technology originates from research at VU University Medical Center in Amsterdam and has received significant innovation funding from the Dutch government[3][4].

Therapeutic areas: Oncology
Modalities: Oncolytic viruses (specifically oncolytic adenoviruses)
Industry: Biotech

Drug pipeline

2 assets

Ad5-D24RGD

1 more asset in the full pipeline.

Partnerships

Dutch Government/Agentschap NL (innovation credit funding)[4]VU University Medical Center/VUmc Amsterdam (technology origin)[4]

Beyond the preview

Go deeper on ORCA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORCA Therapeutics.